Tag: trastuzumab emtansine
Trastuzumab Deruxtecan Shows Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously...
Trastuzumab deruxtecan is revolutionizing the treatment paradigm. Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) led to higher response rates and longer survival...
Trastuzumab Deruxtecan: Longer Overall Survival than Trastuzumab Emtansine in HER2-positive Metastatic...
The second-line treatment with trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) leeds to significantly longer overall survival compared with trastuzumab emtansine (T-DM1; Kadcyla®; Genentech/Roche) in...
FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates
The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...
First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in...
A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of trastuzumab duocarmazine, also known...
Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2...
Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...
2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...
This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...
